Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2002;100:281-287
© 2002 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Itamochi, H.
Right arrow Articles by Terakawa, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Itamochi, H.
Right arrow Articles by Terakawa, N.

ORIGINAL RESEARCH

Low Proliferation Activity May Be Associated With Chemoresistance in Clear Cell Carcinoma of the Ovary

Hiroaki Itamochi, MD, PhD, Junzo Kigawa, MD, PhD, Toru Sugiyama, MD, PhD, Yoshihiro Kikuchi, MD, PhD, Mitsuaki Suzuki, MD, PhD and Naoki Terakawa, MD, PhD

From the Department of Obstetrics and Gynecology, Tottori University, Yonago, Japan; Kurume University, Kurume, Japan; National Defense Medical College, Tokorozawa, Japan; and Jichi Medical School, Utsunomiya, Japan.

Address reprint requests to: Junzo Kigawa, MD, PhD, Tottori University School of Medicine, Department of Obstetrics and Gynecology, 36-1 Nishimachi, Yonago, 6838504, Japan; E-mail: kigawa{at}grape.med.tottori-u.ac.jp.

OBJECTIVE: To estimate whether and how the biologic behavior of clear cell carcinoma contributes to the chemoresistance mechanism.

METHODS: Forty-one patients with clear cell carcinoma and 90 patients with serous adenocarcinoma, who had measurable disease after initial surgery, were examined. All patients underwent cytoreductive surgery followed by platinum-based chemotherapy. P-glycoprotein, multidrug resistance-associated protein, and Ki-67 expression were determined by immunohistochemical staining.

RESULTS: The 5-year survival rate for patients with clear cell carcinoma was significantly poorer, compared with serous adenocarcinoma (20.0% versus 31.9%). Response rate to chemotherapy was 14.6% for clear cell carcinoma and 72.2% for serous adenocarcinoma. The expression of P-glycoprotein and multidrug resistance-associated protein did not differ between responders and nonresponders in both tumor types. The Ki-67 labeling index (LI) in clear cell carcinoma was significantly lower than serous adenocarcinoma (18.4% versus 38.8%). The LI for responders was significantly higher than that for nonresponders in both tumor types. In clear cell carcinoma, the mean value of LI was 15.3% for nonresponders, but that for responders was 30.2%, which was similar to that for serous adenocarcinoma. When the cutoff value of LI was set at 18.4% (mean value), the 5-year survival rate for high LI (over 18.4%) patients was significantly greater than that for low LI patients (46.3% versus 9.2%). Multivariable analysis revealed that LI and residual tumor size were the independent prognostic factors.

CONCLUSION: Lower proliferation of tumor may be a behavior of clear cell carcinoma of the ovary that contributes to its resistance to chemotherapy.




This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
D. S P Tan and S. Kaye
Ovarian clear cell adenocarcinoma: a continuing enigma
J. Clin. Pathol., April 1, 2007; 60(4): 355 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Itamochi, J. Kigawa, Y. Kanamori, T. Oishi, C. Bartholomeusz, R. Nahta, F. J. Esteva, N. Sneige, N. Terakawa, and N. T. Ueno
Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy
Mol. Cancer Ther., January 1, 2007; 6(1): 227 - 235.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Pectasides, E. Pectasides, A. Psyrri, and T. Economopoulos
Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?
Oncologist, November 1, 2006; 11(10): 1089 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Tsuda, Y. M. Ito, Y. Ohashi, K.-K. Wong, Y. Hashiguchi, W. R. Welch, R. S. Berkowitz, M. J. Birrer, and S. C. Mok
Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses
Clin. Cancer Res., October 1, 2005; 11(19): 6880 - 6888.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. K. Zorn, T. Bonome, L. Gangi, G. V.R. Chandramouli, C. S. Awtrey, G. J. Gardner, J. C. Barrett, J. Boyd, and M. J. Birrer
Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer
Clin. Cancer Res., September 15, 2005; 11(18): 6422 - 6430.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. M. Garrity, L. J. Burgart, M. R. Mahoney, H. E. Windschitl, M. Salim, M. Wiesenfeld, J. E. Krook, J. C. Michalak, R. M. Goldberg, M. J. O'Connell, et al.
Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study
J. Clin. Oncol., May 1, 2004; 22(9): 1572 - 1582.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Reed, J. J. Yu, A. Davies, J. Gannon, and S. L. Armentrout
Clear Cell Tumors Have Higher mRNA Levels of ERCC1 and XPB Than Other Histological Types of Epithelial Ovarian Cancer
Clin. Cancer Res., November 1, 2003; 9(14): 5299 - 5305.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Obstetricians and Gynecologists.